Sign In
Buy AB
$36.87
-0.160 (-0.432%)
At Close: Jun 03, 2026
Should Value Investors Buy AllianceBernstein (AB) Stock?
11:17am, Wednesday, 11'th Jan 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
COMMUNIQUE DE PRESSE
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
05:09pm, Thursday, 29'th Dec 2022 GlobeNewswire Inc.
PRESS RELEASE
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
06:04pm, Tuesday, 27'th Dec 2022 GlobeNewswire Inc.
PRESS RELEASE
Le masitinib reçoit la désignation de médicament orphelin pour le traitement de la sclérose latérale amyotrophique en Suisse
06:04pm, Tuesday, 27'th Dec 2022 GlobeNewswire Inc.
COMMUNIQUE DE PRESSE
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
05:10pm, Thursday, 22'nd Dec 2022 GlobeNewswire Inc.
PRESS RELEASE
AB Science annonce le tirage de la première tranche de 6 millions d’euros dans le cadre de son contrat de financement avec la Banque Européenne d’Investissement
05:10pm, Thursday, 22'nd Dec 2022 GlobeNewswire Inc.
COMMUNIQUE DE PRESSE
Buy 10 December Inflation-Busting Dividend Dogs
11:56am, Friday, 16'th Dec 2022
March-April, 2022, UBS, Kiplinger, and Barron's analysts and reporters combined to list five sets of stocks sorted as: “Inflation Busters for 2022.” Those five articles revealed 48 equities, with
T. Rowe Price (TROW) Stock Gains 2.1% as November AUM Increases
01:57pm, Wednesday, 14'th Dec 2022 Zacks Investment Research
T. Rowe Price (TROW) records AUM worth $1.34 trillion for November 2022, reflecting a rise of 4.7% from the previous month.
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
05:08pm, Tuesday, 13'th Dec 2022 GlobeNewswire Inc.
PRESS RELEASE
AB Science a reçu un avis d’insuffisance de l’agence Health Canada pour le masitinib dans la sclérose latérale amyotrophique
05:08pm, Tuesday, 13'th Dec 2022 GlobeNewswire Inc.
COMMUNIQUE DE PRESSE
Invesco (IVZ) November AUM Rises 5.7% on Favorable Markets
03:11pm, Tuesday, 13'th Dec 2022 Zacks Investment Research
Invesco (IVZ) records a 5.7% sequential rise in preliminary assets under management for November 2022.
Earnings will be under pressure next few quarters and most of '23, says Alliance Bernstein's Tierney
01:34pm, Tuesday, 13'th Dec 2022
Jim Tierney, Alliance Bernstein CIO of U.S. concentrated growth, joins 'The Exchange' to discuss what the market is pricing in right now, what Tierney foresees for equity markets and the kind of compa
7 Stocks to Buy to Beat Next Year's Interest Rate Blues
03:30pm, Wednesday, 30'th Nov 2022
With the Federal Reserve committed to tackling historically high inflation through hawkish monetary policies, it's time for investors to consider the best stocks to buy for rising interest rates. Sure
AllianceBernstein and Societe Generale Plan to Form a JV
01:50pm, Thursday, 24'th Nov 2022 Zacks Investment Research
AllianceBernstein (AB) and Societe Generale (SCGLY) decide to form a JV by combining their cash equities and equity research businesses.
